Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI study of Ritlecitinib and Sumatriptan
NCT04355845Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Primary endpoints: Sumatriptan area under the curve extrapolated to infinite time at 48 hours, Sumatriptan maximum plasma concentration at 48 hours and 1 more. Started Jun 2020; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04355845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355845.